Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. Eur J Pharm Sci. 2023 Feb 01; 181:106358.
-
Predictors of CNS-Active Medication Use and Polypharmacy Among Homebound Older Adults With Depression. Psychiatr Serv. 2020 08 01; 71(8):847-850.
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
-
Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia. Neurodegener Dis Manag. 2018 08; 8(4):233-242.
-
Endogenous nitric oxide inhibits spinal NMDA receptor activity and pain hypersensitivity induced by nerve injury. Neuropharmacology. 2017 Oct; 125:156-165.
-
Electrocardiographic characteristics in individuals with cocaine use disorder. Am J Addict. 2017 Apr; 26(3):221-227.
-
Evaluation and Management of Children With Acute Mental Health or Behavioral Problems. Part II: Recognition of Clinically Challenging Mental Health Related Conditions Presenting With Medical or Uncertain Symptoms. Pediatrics. 2016 09; 138(3).
-
Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs. 2016 Mar; 30(3):245-67.
-
Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence. Neuropharmacology. 2015 Oct; 97:182-93.
-
Thiazole: a promising heterocycle for the development of potent CNS active agents. Eur J Med Chem. 2015 Mar 06; 92:1-34.